ALCON Business Summary

Alcon Inc. (ALC) is the global leader in eye care, operating through two primary business segments: Surgical and Vision Care. The Surgical segment generates revenue by selling advanced ophthalmic equipment, such as the Unity surgical platform, alongside high-volume consumables and premium intraocular lenses (IOLs) like the PanOptix and Vivity brands. The Vision Care segment focuses on a diverse portfolio of contact lenses, including the Dailies, Air Optix, and Total30 lines, as well as ocular health products like Systane and Tryptyr for dry eye treatment. Alcon’s business model relies on a "razor-and-blade" strategy, where its massive installed base of surgical equipment drives recurring high-margin sales of specialized consumables. As of March 2026, Alcon maintains its market-leading position against top-tier competitors including Johnson & Johnson Vision, Bausch + Lomb, Cooper Companies, and Carl Zeiss Meditec, distinguishing itself through its massive R&D pipeline and a global footprint that spans over 140 countries. Originally founded in 1945 by pharmacists William Conner and Robert Alexander, Alcon evolved from a small ophthalmic shop into a global powerhouse, eventually spinning off from Novartis as an independent public entity in 2019. The current leadership team is headed by CEO David J. Endicott, who previously served as President of Hospira Infusion Systems (a Pfizer company) and has been instrumental in Alcon's post-spin operational acceleration. He is supported by Senior VP and CFO Tim Stonesifer, a veteran finance executive with prior leadership roles at Hewlett Packard, General Motors, and General Electric, and Franck Leveiller, who serves as Chief Scientific Officer and Head of Global R&D. The company’s governance is further strengthened by a distinguished board of directors, which recently added Deborah Di Sanzo, former President of Best Buy Health and CEO of IBM Watson Health, to bolster its digital health and technological integration strategies.